The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.

Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.

Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Naresh Bumma, MD, discusses the focus of each presentation on frontline therapy, early and late relapse, and CAR T-cell therapy in multiple myeloma.

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

John C. Byrd, MD, discusses the rationale for the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.